We originally reported on this cancer cure story a few weeks back. Subsequently, a lot of red flags started appearing about the AEBi (Accelerated Evolution Biotechnologies, Ltd), including:
- The cancer cure would be available from day one and the subject will be completely cancer free within a year.
- That AEBi offered no evidence for its claim, only that they did not have enough funding to produce peer-reviewed publications.
- laims to be able to cure all forms of cancer.
- A notable cancer research scientist reported in a Forbes that the AEBi claimed to attack cancer cells three at a time, which is strange since cancer cells themselves can’t do that.
The following excerpts were originally reported by NoCamels.com
The new development was picked up by numerous media publications in Israel and across the world. Meanwhile, AEBi offered no evidence of its findings and claimed not to have the funds to publish any in peer-reviewed scientific journals.
But the company says its developed treatment, MuTaTo (multi-target toxin), is a new, multi-pronged attack on cancer cells using peptides that showed “consistent and repeatable” results in the “first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials,” the Jerusalem Post reported.
Dr. Victoria Forster, a cancer research scientist and postdoctoral fellow at The Hospital for Sick Children (SickKids) in Toronto, Canada, wrote in a Forbes piece that the first “red flag” for her was a claim by AEBi’s CEO Dr. Ilan Morad on what the treatment could achieve.
“Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time,” Morad had told the Jerusalem Post.
“This is categorically untrue,” wrote Forster. “Cancers can have anywhere from one to tens of thousands of DNA mutations in their genomes, many of these being the ‘receptors’ Morad vaguely refers to. A key principle of using multiple chemotherapy agents at once is to go after cancer cells by several different routes to reduce the chance that they will become resistant. Still, many cancers do become resistant to these treatment protocols, so Morad’s logic here is extremely shaky.”
Furthermore, the Israeli company’s claim that its treatment will work for all types of cancers is also a “huge red flag,” she said.
“There are broadly over 200 different types of cancer and within those, multiple other subtypes. For there to be one, universal ‘cancer cure’ that overcomes all of these differences is highly unlikely,” Forster charged.
An Australian cancer research scientist went a step further, accusing the company of “selling unicorns” and calling for it to be hung out “to dry for making such cruel and misleading claims.”
In reference to popular culture, cancer biologist Dr. Darren Saunders said
Dr. J. Leonard Lichtenfeld, the deputy chief medical officer for the national office of the American Cancer Society, wrote in a blog post titled “A Cure For Cancer? Not So Fast” that while the Israeli scientists “worked with an interesting approach to interfering with the ability of cancer cells to function,” they provided very limited information that has “not been published in the scientific literature where it would be subject to review, support and/or criticism from knowledgeable peers.”
He further noted that AEBi’s initial experiment on mice in clinical trials “is not a well-established program of experiments which could better define how this works—and may not work—as it moves from the laboratory bench to the clinic.”
“The gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is, in fact, a long and treacherous journey, filled with unforeseen and unanticipated obstacles,” Lichtenfeld wrote, pouring cold water on the claim that the treatment would be available in a year.